Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Charles River Laboratories InternationalCRL -0.08%69 Days Sales Outstanding is 64.16 as of Jun. 2026, which is 24% above its 10-year median of 51.88. GuruFocus rates CRL with a GF Score™ of 69/100 and a GF Value™ of $194.23 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Charles River Laboratories International ranks better than 71.64% on this metric.
CRL's Days Sales Outstanding is ranked better than 71.64% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs CRL: 48.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International Days Sales Outstanding Chart
Charles River Laboratories International Annual Data
CRL vs RVTY, ICLR, MEDP: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's Days Sales Outstanding falls into.
Charles River Laboratories International Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International (CRL) has a Days Sales Outstanding of 64.16 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Charles River Laboratories International and its competitors. This is 24% above median its historical median of 51.88. Over the past decade, Charles River Laboratories International's Days Sales Outstanding has ranged from 47.56 to 60.90. According to the industry distribution chart, Charles River Laboratories International ranks #57 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 28.4%.
Is Charles River Laboratories International's Days Sales Outstanding too high?
Charles River Laboratories International's current Days Sales Outstanding of 64.16 is 24% above median its 10-year median of 51.88. Over the past 10 years, this metric has ranged from a low of 47.56 to a high of 60.90. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Charles River Laboratories International's value of 64.16 is 5.1% below this industry median. Based on the distribution chart, Charles River Laboratories International ranks #57 out of 201 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Days Sales Outstanding compare to RVTY and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #57 out of 201 companies for Days Sales Outstanding. This puts Charles River Laboratories International in the upper half of its industry. The industry median Days Sales Outstanding is 67.59. Charles River Laboratories International's value of 64.16 is 5.1% below this benchmark. Historically, Charles River Laboratories International's own Days Sales Outstanding has ranged from 47.56 to 60.90 over the past decade. While the company's 10-year median is 51.88 vs. the industry median of 67.59, Charles River Laboratories International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current Days Sales Outstanding of 64.16 is 5.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current Days Sales Outstanding is 64.16, which is 24% above median its own 10-year median of 51.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is $194.23, compared to a current price of $272.88 — trading 40.5% above its estimated fair value. The current Days Sales Outstanding is 64.16, which is 24% above median its 10-year median of 51.88 and 5.1% below the Medical Diagnostics & Research industry median of 67.59. Charles River Laboratories International's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current Days Sales Outstanding is 64.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $272.88 is trading 40.5% above its estimated GF Value™ of $194.23.
GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.
Key valuation signals for CRL:
Days Sales Outstanding: 64.16 (24% above median its 10-year median of 51.88)
GF Value™: $194.23 vs. price of $272.88 (40.5% above fair value)
Industry Position: 5.1% below the Medical Diagnostics & Research median (#57 of 201)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
69GF Score
Get the complete analysis for CRL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
